Articles related to LYMPHOMA

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

Amid emerging safety concerns, ADC Therapeutics has paused its mid-stage trial of Zynlonta, a potential game-changer in treating certain types of blood cancer, calling into question the drug’s future trajectory.

Explore the newest developments in lymphoma therapy with the help of this CME program, learn how effective bispecific antibodies and antibody-drug conjugates are, and fine-tune your therapeutic approaches.

The study findings suggest that acalabrutinib and rituximab, a chemo-free therapy option, may offer a new standard of care for older, untreated MCL patients, with promising early complete responses. Yet, more data is needed to understand long-term safety and risk of relapse.

FIL-ROUGE trial data presented at the International Conference on Malignant Lymphoma 2023 highlight the potential of intensified ABVD in improving outcomes for untreated Hodgkin lymphoma patients. Further exploration of this regimen’s long-term toxicity is anticipated.